159 related articles for article (PubMed ID: 455886)
1. Presystemic and systemic glucuronidation of propranolol.
Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of glucuronidation of propranolol following oral administration in humans.
Midha KK; Roscoe RM; Wilson TW; Cooper JK; Loo JC; Ho-Ngoc A; McGilveray IJ
Biopharm Drug Dispos; 1983; 4(4):331-8. PubMed ID: 6661512
[TBL] [Abstract][Full Text] [Related]
3. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.
Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
Clin Pharmacol Ther; 1980 Jan; 27(1):22-31. PubMed ID: 7351114
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.
Walle T; Walle UK
Res Commun Chem Pathol Pharmacol; 1979 Mar; 23(3):453-64. PubMed ID: 461970
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of propranolol in the dog.
Tse FL; Sanders TM; Reo JP
Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
[TBL] [Abstract][Full Text] [Related]
6. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade.
Wilson TW; Firor WB; Johnson GE; Holmes GI; Tsianco MC; Huber PB; Davies RO
Clin Pharmacol Ther; 1982 Dec; 32(6):676-85. PubMed ID: 7140133
[TBL] [Abstract][Full Text] [Related]
7. No stereoselective first-pass hepatic extraction of propranolol.
Jackman GP; McLean AJ; Jennings GL; Bobik A
Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective increase in propranolol bioavailability during chronic dosing in the dog.
Bai SA; Wilson MJ; Walle UK; Walle T
J Pharmacol Exp Ther; 1983 Nov; 227(2):360-4. PubMed ID: 6631718
[TBL] [Abstract][Full Text] [Related]
9. Direct measurement of propranolol bioavailability during accumulation to steady-state.
Wood AJ; Carr K; Vestal RE; Belcher S; Wilkinson GR; Shand DG
Br J Clin Pharmacol; 1978 Oct; 6(4):345-50. PubMed ID: 698031
[TBL] [Abstract][Full Text] [Related]
10. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
[TBL] [Abstract][Full Text] [Related]
11. Partial metabolic clearances as determinants of the oral bioavailability of propranolol.
Walle T; Walle UK; Olanoff LS; Conradi EC
Br J Clin Pharmacol; 1986 Sep; 22(3):317-23. PubMed ID: 3768243
[TBL] [Abstract][Full Text] [Related]
12. The effect of ageing on the hepatic clearance of propranolol.
Castleden CM; George CF
Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
[TBL] [Abstract][Full Text] [Related]
13. The relative bioavailability of a commercial propranolol hydrochloride tablet in man.
Roscoe R; Cooper J; Wilson TW; Joshi NN; Midha KK
Biopharm Drug Dispos; 1982; 3(2):105-14. PubMed ID: 7104460
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man.
Cid E; Mella F; Lucchini L; Cárcamo M; Monasterio J
Biopharm Drug Dispos; 1986; 7(6):559-66. PubMed ID: 3828485
[TBL] [Abstract][Full Text] [Related]
15. Kinetics and cardiac effects of propranolol in humans.
Ochs HR; Grube E; Greenblatt DJ; Knüchel M; Bodem G
Klin Wochenschr; 1982 May; 60(10):521-5. PubMed ID: 7098380
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective disposition and glucuronidation of propranolol in humans.
Silber B; Holford NH; Riegelman S
J Pharm Sci; 1982 Jun; 71(6):699-704. PubMed ID: 7097538
[TBL] [Abstract][Full Text] [Related]
17. Influence of food on the intravenous and oral dose kinetics of propranolol in the dog.
Bai SA; Walle UK; Walle T
J Pharmacokinet Biopharm; 1985 Jun; 13(3):229-41. PubMed ID: 4087163
[TBL] [Abstract][Full Text] [Related]
18. Propranolol glucuronide cumulation during long-term propranolol therapy: a proposed storage mechanism for propranolol.
Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
Clin Pharmacol Ther; 1979 Dec; 26(6):686-95. PubMed ID: 498710
[TBL] [Abstract][Full Text] [Related]
19. Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing.
Wells PG; Feely J; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1983 May; 33(5):603-8. PubMed ID: 6839632
[TBL] [Abstract][Full Text] [Related]
20. Mechanism by which hydralazine increases propranolol bioavailability.
Schneck DW; Vary JE
Clin Pharmacol Ther; 1984 Apr; 35(4):447-53. PubMed ID: 6705442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
